Purpose Borderline ovarian tumors (BOTs) are more common in young women of reproductive age, and exhibit a better prognosis than malignant ovarian tumors (MOTs). Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were compared in their ability to differentiate BOTs from stage I MOTs. Methods Among 173 patients who had preoperative FDG PET/CT due to ovarian neoplasms between November 2006 and March 2009, there were 13 patients with BOTs or stage I MOTs. For differential diagnosis of the two tumors, cancer antigen-125 (CA-125) level, the longest diameter of tumors, metabolic indices including maximum standardized uptake value (SUV max ), and volumetric indices including metabolic tumor volume (MTV) were compared, respectively. Results The BOT group (n=7) was comprised of five mucinous and two serous tumors, and the MOT group (n=6) was comprised of three endometrioid, two clear cell and one mucinous tumors. Among the comparisons between two groups, SUV max of the BOT group was significantly lower than that of the MOT group (2.9±1.5 vs. 6.6±2.9, p=0. 0223); otherwise, no significant difference was found in age, CA-125, diameter, or MTV. By receiver-operating characteristic curve analysis, SUV max of 3.7 was the best cutoff value to differentiate BOTs from stage I MOTs, with a sensitivity of 83.3 % and specificity of 85.7, and the area under curve of 0.893 (p=0.0001, 95 % CI: 0.601∼0.993). Conclusions We demonstrated that SUV max could distinguish BOTs from stage I MOTs, with a high sensitivity and specificity. Metabolic indices determined by FDG PET/CT were more suitable than volumetric indices for differential diagnosis of the two tumors.
Introduction
Borderline ovarian tumors (BOTs) were distinctly categorized by the International Federation of Gynecology and Obstetrics (FIGO) in 1971, and comprise up to 15-20 % of epithelial ovarian neoplasms, which histologically demonstrate cellular proliferation but not destructive stromal invasion [1, 2] . BOTs are more common in young women of reproductive age, and exhibit a better prognosis than malignant ovarian tumors (MOTs) [3] . In regard to the primary treatment of BOTs, conservative management, such as unilateral salpingo-oophorectomy (USO) with comprehensive staging, suffices women wanting to preserve fertility; otherwise, radical management, such as a bilateral salpingo-oophorectomy (BSO) with total abdominal hysterectomy (TAH) including comprehensive staging, is required to reduce tumor recurrence. These therapeutic strategies are worthwhile, considering that BOTs are notoriously resistant to platin-based chemotherapy [4] .
MOTs can metastasize to the contralateral ovary, peritoneal cavity, and retroperitoneal lymph nodes, even during early stage disease [1] . Therefore, they should be treated more radically by, for example, BSO with TAH, omentectomy, and complete surgical staging. Furthermore, adjuvant chemotherapy should be administered to reduce tumor recurrence. Accordingly, the differential diagnosis of BOTs from early stage MOTs is important, because this differentiation can influence surgical management, prognosis, and the possibility of fertility-preserving surgery, especially in young patients.
Various diagnostic methods, including tumor markers and imaging modalities, have been used to differentiate BOTs from MOTs. Cancer antigen 125 (CA-125) has been extensively studied as a biomarker for MOTs, but it exhibits poor sensitivity during the early disease stage and low specificity for malignancy [5] . In particular, it has been reported that CA-125 did not increase in one half of early stage MOT cases, and that serum CA-125 levels failed to differentiate BOTs from MOTs [1, 6] . Diagnostic imaging modalities, including computed tomography (CT) and magnetic resonance imaging (MRI), have been performed to assess pelvic masses preoperatively. However, the confident differentiation of BOTs from stage I MOTs was not possible, because these two diseases share morphological features [1] .
Positron emission tomography/computed tomography (PET/CT) with F-18 fluorodeoxyglucose (FDG) has been widely used for preoperative staging, predicting prognosis, and detecting the recurrence of ovarian cancers, because it provides a combination of functional and anatomical imaging [7, 8] . However, the clinical role of FDG PET/CT for the differentiation of BOTs from early stage MOTs is doubtful [9] . Thus, we evaluated the diagnostic abilities of FDG PET/CT to differentiate BOTs from early stage (FIGO stage I) MOTs.
Material and Methods

Patients
We retrospectively reviewed preoperative FDG PET/CT and MR images obtained between November 2006 and March 2009, to evaluate adnexal masses suspicious of a primary ovarian neoplasm in 173 patients at our institute. Of these 173 patients, 13 with pathologically proven epithelial ovarian tumors of either early stage MOT (FIGO stage I) or BOT were enrolled in this study. The remainder of the patients had advanced stage ovarian cancer or non-epithelial ovarian tumors, such as mature teratomas. The enrolled patients were allocated to BOT or MOT groups. The BOT group comprised seven patients (48.9±19.6 y; range 14-73 y), and the MOT group comprised six patients (60.0±11.0 y; range 48-77 y). This study was approved by the institutional review board at Seoul National University Hospital, and the requirement for informed consent was waived due to the retrospective design of the study.
Serum CA-125
Serum levels of CA-125 were measured preoperatively in all the patients. Times between preoperative CA-125 measurements before surgery were not significantly different in the two groups (BOT 8.7±4.7 days vs. MOT 11.7±10.2 days, p= 0.8864). Serum CA-125 levels were determined in duplicate using a radioimmunoassay (Fujirebio Diagnostics, Malvern, PA, USA), which had a range up to 500 U/ml. Within-assay and between-assay variation coefficients were < 4.3-8.2 % and < 5.2-8.3 %, respectively.
PET/CT
Whole body PET/CT images were acquired using dedicated PET/CT systems (Biograph 40, Siemens Healthcare, Erlangen, Germany; Gemini, Philips Medical Systems, Andover, USA). Patients fasted at least 4 h prior to PET/CT scanning, furosemide (20 mg) was intravenously administered and a Foley catheter was placed to minimize urine FDG activity. FDG (5.18 MBq/kg) was administered intravenously, and 125 ml of a barium sulfate solution (EZCT [1.5 % weightvolume barium sulfate suspension], Taejoon Pharm, Seoul) was administered orally 1 h prior to scanning. A CT scan (80 mA and 140 kVp) was performed for attenuation correction prior to PET scans. CT scans were obtained using a 5-mm section thickness from the skull base to the mid-thigh; images were reconstructed using a 512×512 matrix, and a 50-cm field of view. PET scans were obtained from the midthigh to the skull base, and images were reconstructed with a 128×128 matrix, using the ordered subset expectation maximum iterative reconstruction algorithm, an 8-mm Gaussian filter, and a 50-cm field of view. In addition, all patients were requested to fill out a questionnaire that contained questions on patients' information, including fasting time, menstruation period, etc.
MR Technique
MR images were obtained on a 3T or 5T scanner (SIGNA EXCITE, GE Medical Systems, Milwaukee, USA) using a phased array and a body coil for pelvic imaging. Scans were obtained using variable sequences; an axial fast spin-echo T1-weighted sequence; an axial, coronal, and sagittal fast spinecho T2-weighted sequence; and an axial fat-saturated spoiled gradient-echo T1-weighted sequence. In addition to routine T1-and T2-weighted images of slice thicknesses 5-to 6-mm, axial fast spin echo T1-wighted fat-suppressed (TR/TE 600/13. 5) with gadolinium contrast enhanced images were obtained at a slice thickness of 8-mm and a 256×128 matrix.
PET Parameter Analyses
Four specific PET parameters, which included both metabolic and volumetric indices, were adopted to differentiate BOTs from early stage MOTs. To acquire PET parameters, in each case, a volume of interest (VOI) was placed on the adnexal mass using a vendor-provided automated contouring program (Volumetric Analysis [version 6.0.14.4], Siemens Healthcare, Erlangen, Germany). The program was set for two different thresholds; a fixed standardized uptake value (SUV) of 1.5, or 50 % of maximum SUV (SUV max ) of the mass. The criteria for the thresholds used here were determined to include all the lesions, since the lowest value of SUV max was 1.52, or to be based on the fact that 50 % of SUV max was reasonable by phantom studies [10] .
SUV max , average SUV (SUV avg ), metabolic tumor volume (MTV), and total lesional glycolysis (TLG) were measured in each VOI at the two thresholds, respectively. SUVs were calculated as follows: SUV ¼ FDG ½ activity concentration ðBq=mlÞ Â total lean body weight kg ð Þ ½ = injected FDG activity Bq ð Þ ½
. MTV was measured after converting FDG PET/CT data in Digital Imaging and Communications in Medicine format, as previously described 8 ; voxels presenting SUVs greater than thresholds within a contouring margin were counted when determining MTVs. Lastly, TLG was defined as the product of SUV avg and MTV within the VOI. Figure 1 shows examples of how PET parameters were acquired at the two different thresholds.
Statistical Analysis
Statistical analysis was performed using MedCalc software (version 12.0; MedCalc Software, Belgium). Statistical significance was accepted for p values of < 0.05. The MannWhitney test for independent samples was used to compare group parameters. Receiver-operating characteristic curve (ROC) analysis with respect to SUV max was performed to determine the best cutoff value for differentiating BOTs from stage I MOTs. The right-sided Grubb's test was performed to detect outliers for the comparisons of serum CA-125 levels.
Results
Clinical Characteristics
Thirteen patients diagnosed with an epithelial ovarian tumor, either early stage MOT (FIGO stage I) or BOT were finally enrolled from among the 173 patients initially reviewed. The excluded patients had advanced stage ovarian cancer or a non-epithelial ovarian tumor. Pathological results revealed the BOT group (n=7) comprised of five mucinous and two serous tumors, and that the MOT group (n=6) comprised of three endometrioid, two clear cell, and one mucinous tumor. In regard to surgical stages, the BOT patients were all of FIGO stage Ia, and the MOT patients were of FIGO stages 4 Ia, 1 Ib, or 1 Ic.
All patients in the MOT group underwent radical surgery, including TAH with BSO and pelvic lymph node dissection (PLND). On the other hand, patients in the BOT group underwent various types of surgery according to the primary purposes of treatment and clinical conditions. USO or tumorectomy (n=4), whether combined with TAH or not, was performed on those with incidentally detected BOT during workup for liver transplantation, rectal cancer, or PeutzJegher syndrome, or during follow-up for adenomyosis after TAH. Complete surgical staging, including TAH with BSO and PLND, was performed in three patients under clinical suspicion of a malignant ovarian tumor.
No significant difference was found between the clinical and demographic characteristics of the two groups. BOT patients tended to be younger, but this was statistically insignificant (48. 9±19.6 vs. 60.0±11.0, p=0.2949). During the comparative analysis of serum CA-125 levels, one patient in the MOT group was found to have an extremely high level (43,530 U/mL). After excluding this patient as an outlier, mean serum CA-125 levels were not significantly different in the BOT and MOT groups (74.7±115.5 vs. 90.8 ± 131.9, p = 0.6623). Diameters of tumors varied from 3.7 cm to 28.0 cm, but no significant intergroup difference was found (BOT: 13.9±8.6 vs. MOT: 16.1± 9.1, p=0.6171). Table 1 summarizes the demographic and clinical characteristics of the two groups.
Comparisons of Image Findings
Image characteristics were compared using MR and FDG PET/CT images. The two groups shared anatomical features on MR images. All tumors were septated and multiloculated with solid elements, including smooth round nodules and papillary projections, with no tendency for any specific feature to predominate in malignancy, such as omental cake, peritoneal nodules, or lymphadenopathy. For both groups, none was a simple unilocular cyst. Ascites was seen in four out of the 13 patients; the others had no definite ascites (n=8) or a small amount of free fluid (n=1) in the abdominoperitoneal cavity. On FDG PET/CT images, only mildly increased hypermetabolic activity was seen in the solid portions of BOTs, whereas intense hypermetabolic activity was seen in MOTs. Representative images of both groups are displayed in Fig. 2 .
The PET parameters consisted of SUV max , SUV avg , MTV, and TLG ( Table 2 ). As mentioned above, SUV max was significantly lower in the BOT group than in the MOT group (2.9±1.5 vs. 6.6±2.9, p=0.0223). To exclude the potential influence of metabolic variations caused by the menstrual cycle [11, 12] , SUV max were re-compared after excluding three patients who were at mid-cycle of menstruation. According to self-questionnaire answers and the medical record review, nine of the 13 patients were menopausal and four were premenopausal. Of these four patients, two in the BOT group and one in the MOT group were at midcycle at the time of FDG PET scanning. Consequently, after excluding three patients who were at the mid-cyle, it was reaffirmed that BOTs had lower SUV max than those of MOTs (2.5±1.0 vs. 7.0±4.1, p=0.0317; Fig. 3) .
Comparisons of volumetric indices were performed using two different thresholds. At the first threshold (SUV max of 1. 5), SUV avg in the BOT tended to be lower than that in the MOT, but it failed to reach a significant level by a close call (1.9±0.3 vs. 2.6±0.7, p=0.0513). However, SUV avg in the Fig. 1 Fig. 4 .
Discussion
In the present study, we investigated the diagnostic abilities of FDG PET/CT to differentiate BOTs from early stage MOTs. Of the various PET parameters examined, SUV max best differentiated the BOTs and early stage MOTs; SUV max had a sensitivity of 83.3 % and a specificity of 85.7 % at the optimal cutoff of 3.7. Tumor-volume-based analyses of TLG and MTV revealed these variables could not differentiate the BOTs and early stage MOTs, and anatomical features and tumor markers were not significantly different for the BOTs and early stage MOTs. It is difficult to differentiate BOTs from early stage MOTs using conventional diagnostic tools, such as anatomical imaging modalities and tumor markers. Furthermore, their MR relaxation characteristics were not useful, since solid components are usually depicted as intermediate signal intensities on both T1-weighted and T2-weighted images of BOTs and early stage MOTs [1] . Contrast MRI enhancement and anatomical features, such as increased septal thickness and solid portion sizes could be helpful, but cannot be used to confidently differentiate these entities [1, 13] . Although CA-125 is a well-known biomarker for the detection of ovarian cancer recurrence, with high accuracy and a high positive predictive value [14] , CA-125 levels were only found to be marginally increased in patients with BOT [15] .
In the present study, SUV max was found to be useful for the differential diagnosis of BOTs from early stage MOTs, with high sensitivity and specificity. More specifically, BOTs had lower SUV max values than early stage MOTs, which can be explained by the physiology of glucose metabolism in these tumors. Glycolysis increases under anaerobic condition (the Warburg effect), and is a characteristic of [16] , and overexpression of glucose transporters such as glucose transporter 1 (GLUT-1) to cope with facilitated glucose consumption is also commonly observed in various malignant tumors. It was reported that expression level of GLUT-1 in epithelial ovarian tumors increased gradually from borderline to malignant tumors [17] . FDG PET utilizes this fundamental characteristic of malignant cells, and thus the lower SUV of BOT infers a lower malignant potential. Adding to the malignant potential, SUV values are known to be an important factor in evaluation of treatment response and prognosis prediction in various malignant tumors. It has been reported that GLUT-1 expression, a major determining factor of SUV values, was related to prognosis of malignant tumors [11, 12] . It was suggested that GLUT-1 expression might be an independent prognostic factor in colon cancer [12] . As for malignant ovarian tumors, potential roles of GLUT-1 expression in predicting prognosis remain unclear, but an article recently published by Chung et al. provides a clue to this matter [18] . They reported that the preoperative metabolic tumor burden and its distribution measured by SUV values could predict recurrence in patients with epithelial ovarian cancer. Similarly, it has been reported that the metabolic tumor burden measured by FDG PET could be an independent prognostic factor for tumor recurrence in patients with early stage of cervical cancer [19] . Since metabolic tumor burden generally reflects the total amount of tumor glycolysis, GLUT-1 expression might be related with the prognosis of epithelial ovarian cancer patients.
SUV values were also reported to be associated with histologic grades of epithelial ovarian tumors [17] . Kurokawa et al. reported that SUV values differed by histologic types of epithelial ovarian tumors which was mainly mediated by the expression level of GLUT-1. Among various histologic types of epithelial ovarian tumors, mucinous tumors are typical tumors presenting low SUV values. In this context, considering histologic types of the study population, the difference of SUV max between the BOT and MOT groups could be explained. In the present study, only one patient had mucinous adenocarcinoma and its SUV max was 3.5; this was the lowest value in the MOT group. On the contrary, the BOT group mainly consisted with mucinous tumor (n=5/7), and the average value of SUV max was 2.0. Mucinous adenocarcinomas account for less than 5 % of all epithelial ovarian cancers, whereas up to 80 % of mucinous tumors are benign or borderline tumors [20] . Thus, it could be useful to measure preoperatively SUV values in predicting histologic type of epithelial ovarian tumors, especially combining with anatomical imaging findings by CT or MR.
SUV provides a measure of the activity within a region of interest, and is the most commonly used PET or PET/CT derived functional biomarker. Furthermore, SUV max has become a standard parameter in oncology field, since it reflects the most active part of a tumor. However, this unique property of SUV max causes unexpected problems associated with high intra-tumoral heterogeneity. For example, in response to anti-cancer therapy, tumor cells can exhibit various changes in glucose metabolism and many other biological processes, and thus SUV max is probably not a 'proper' indicator of metabolic change in an entire tumor. To overcome this shortcoming, volumetric indices, such as TLG and MTV, have been utilized as alternatives to SUVs.
TLG and MTV have been actively investigated in the contexts of treatment response evaluation, objective patient monitoring, and treatment planning. MTV is the tumor volume determined by PET using the segmentation technique, and TLG is the product of MTV and SUV avg within a lesion at a certain threshold [21] . Given that TLG provides a measure of tumor global metabolic activity and MTV provides a measure of tumor volume with a FDG uptake greater than a threshold value, TLG and MTV could both provide a better measure of treatment response or tumor burden than SUVs. Indeed, a change in TLG has been shown to be a strong predictor of treatment response in many cancers.
To examine the usefulness of volumetric indices, we applied TLG and MTV to the differential diagnosis of BOTs and early stage MOTs. Two different thresholds were used for volumetric indices; that is, a fixed SUV max of 1.5 or 50 % of SUV max . Contrary to our expectations, TLG and MTV did not differentiate BOTs from early stage MOTs, but average SUVs within the thresholds were significantly different in the two groups, which were consistent with the SUV max analysis results, because SUV avg also reflects metabolism in solid tumor regions. Comparisons of SUV avg values in two groups were more significantly different at a threshold of 50 % of SUV max (p=0.0140) than at a threshold of 1.5 (p=0.0513). In general, the 50 % threshold contained portions of tumors smaller than the 1.5 threshold, because the latter threshold was chosen to include all tumor regions showing low FDG uptake. Thus, SUV avg at a threshold of 50 % was closer to SUV max than SUV max at a threshold of 1.5.
The failure of the volumetric indices, TLG and MTV, to significantly differentiate BOTs from early stage MOTs can be explained by the anatomical characteristics of ovarian tumors. Epithelial ovarian tumors are generally cystic, and solid portions are associated with malignancy. Accordingly, volumetric indices tend to be exaggerated by cystic regions, whereas metabolic indices, which provide measures of the metabolic activities of solid tumor portions, are not influenced by the sizes of cystic regions. Accordingly, our results indicate that metabolic indices are more appropriate for the evaluation of tumors containing cystic portions.
The present study is inherently limited by its retrospective design, the small number of patients recruited, and by the fact that it was conducted at a single institution. Usually, patients with adnexal masses strongly suspected to be BOTs by conventional anatomical imaging are not further examined by FDG PET, due to clinical and cost considerations. Actually, only patients with BOTs incidentally found during FDG PET studies for other medical conditions were enrolled in this study. For this reason, mean age in the BOT group was not significantly different from that of the MOT group. Because of the older age of our cohort, the potential influence of menstruation on FDG uptake by ovarian tumors was minimal (only four patients were premenopausal). We also re-compared SUV max values after excluding three patients in mid menstrual cycle, because ovarian uptake peaks at this time [22, 23] , and the result of the comparison confirmed that SUV max values remained significantly different. A prospective larger-scale study including young patients of reproductive age is suggested to reaffirm diagnostic values of FDG PET/CT in differentiating BOTs from early MOTs.
Conclusions
This study shows that SUV max values can distinguish BOTs from early stage MOTs, with a high sensitivity and specificity. However, novel PET/CT tumor volume associated indices failed to differentiate the BOTs and early stage MOTs. Accordingly, our results show that metabolic indices determined by PET/CT are more suitable than volumetric indices for the evaluation of ovarian tumors containing cystic portions.
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